Nat. Rev. Cardiol. doi: /nrcardio

Slides:

Advertisements

Similar presentations

THE USE OF A TRANSCATHETER AORTIC VALVE TO REPLACE A DEFECTIVE AORTIC VALVE WITHOUT OPEN-HEART SURGERY Natalie Garda and Adam Cotter Heart disease is the.

Advertisements

University Heart Center Hamburg

Date of download: 5/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Transcatheter Valve-in-Valve and Valve-in-Ring for.

TAVR for the Treatment of Pure Native Aortic Valve Regurgitation

Nat. Rev. Cardiol. doi: /nrcardio

A: The Edward SAPIEN balloon expandable valve (Edwards Lifesciences, Irvine, CA) incorporates a stainless steel frame, bovine pericardial leaflets, and.

PROTESI VALVOLARI CARDIACHE:

Nat. Rev. Cardiol. doi: /nrcardio

Design & Product Development Larry L Wood

Optimizing Valve Sizing: Role of CT vs. Echo

Transcatheter Aortic Valve-in-Valve Implantation for Patients With Degenerative Surgical Bioprosthetic Valves Danny Dvir, MD, Marco Barbanti, MD, John.

TAVR-Endocarditis Tarek Chami, MD

Review of the Latest OUS Data from the Self-Expanding Valve Studies

TAVR Requirements for the Cath Lab

WEBSITE Global Transcatheter Aortic Valve Replacement (TAVR) Market: Analysis By Type of Approach (Transfemoral and Transapical),

Nat. Rev. Cardiol. doi: /nrcardio

Second Generation Valves: What Will Be Different?

University Heart Center Hamburg

A: Edwards Sapien percutaneous aortic valve (Reproduced with permission from Edwards Lifesciences, Irvine, California.) B: Medtronic CoreValve, currently.

Valvular Heart Disease: Classic Teaching and Emerging Paradigms

Nat. Rev. Cardiol. doi: /nrcardio

Figure 10 Assessment of myocardial fibrosis

Figure 5 TAVI with a self-expanding valve in

Nat. Rev. Cardiol. doi: /nrcardio

Figure 8 Implanted devices for the management of heart failure

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Pathological specimens showing the most common reasons for bioprosthetic valve failure Figure 2 | Pathological specimens showing the most common.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 3D printing of aortic and mitral valves

Figure 8 4D magnetic resonance imaging patterns

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Valve-in-valve implantations in degenerated surgical valves

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Health-care system today

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 Cardiovascular risk and disease across the life-course

Transatlantic editorial on transcatheter aortic valve replacement

Figure 1 Decision tree integrating the assessment,

Figure 4 TAVI for bicuspid aortic valve disease

Figure 1 Types of surgical and transcatheter aortic valves

Figure 2 Global cost of HF per capita in 2012

Figure 2 A patient with aortic stenosis and mitral regurgitation

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

A.A. Klein, S.T. Webb, S. Tsui, C. Sudarshan, L. Shapiro, C. Densem

Nat. Rev. Cardiol. doi: /nrcardio

Cardiac Critical Care After Transcatheter Aortic Valve Replacement

Figure 6 The neurogenic components of angina

Suggested pathway for assessment of aortic valve replacement dysfunction. Suggested pathway for assessment of aortic valve replacement dysfunction. Transthoracic.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Stent and leaflet stresses in a 26-mm first-generation balloon-expandable transcatheter aortic valve Yue Xuan, PhD, Kapil Krishnan, PhD, Jian Ye, MD,

Nat. Rev. Cardiol. doi: /nrcardio

Jamil Aboulhosn et al. JCIN 2017;10:53-63

(A) CUSUM analysis for the primary end point (VARC-2 safety end point at 30 days composite of: death, stroke, life-threatening bleeding, major vascular.

Nat. Rev. Cardiol. doi: /nrcardio

Deterministic univariate sensitivity analyses (BAV, balloon aortic valvuloplasty; ICU, intensive care unit; MM, medical management; QALY, quality-adjusted.

Transcatheter aortic valve implantation: The European experience

Nat. Rev. Cardiol. doi: /nrcardio

Presentation transcript:

Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.82 Figure 4 Commercially available and investigational devices for transcatheter aortic valve implantation Figure 4 | Commercially available and investigational devices for transcatheter aortic valve implantation. Valves are grouped into those that are delivered mounted on a balloon for delivery, those that are unsheathed as a self-expanding design, and those with a unique delivery mechanism. Of the devices pictured, only the Edwards SAPIEN XT and S3 balloon expandable valves and the Medtronic Evolut-R self-expanding valves are currently approved for commercial use by the FDA. The device manufacturers' details from left to right, top to bottom: SAPIEN, SAPIEN XT, SAPIEN 3 (Edwards Lifesciences, USA); Colibri Heart Valve (Colibri, USA); CoreValve, CoreValve Evolut-R (Medtronic, USA); Portico (St. Jude Medical, USA); Venus (Medtech, China); ACURATE (Boston Scientific, USA); LOTUS Edge (Boston Scientific, USA); JenaValve (JenaValve, Germany), Meridian (Heart Leaflet Technologies, Italy). Images reprinted with permission from the companies indicated in the Figure. Images reprinted with permission from the companies indicated in the Figure. Jones, B. M. et al. (2017) Matching patients with the ever-expanding range of TAVI devices Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.82